XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
SHARE OPTION PLANS AND ESPP (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of June 30, 2023 and changes during the period then ended is presented below:
Six months ended June 30, 2023
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year8,786,364 $37.27 
Granted779,388 74.07 
Exercised(704,027)13.93 
Forfeited and canceled(239,866)75.47 
Outstanding as of June 30, 20238,621,859 $41.44 
Exercisable options6,862,376 $30.57 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of June 30, 2023 and changes during the period then ended is presented below.
Six months ended June 30, 2023
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year5,377,459 $66.87 
Granted1,267,758 76.04 
Vested(770,163)84.96 
Forfeited and cancelled(121,741)92.59 
Unvested as of June 30, 2023 (1)5,753,313 65.95 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of June 30, 2023, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
 June 30, 2023
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
2,703,852 $48.16 $130,218 
189,029 76.97 14,550 
124,701 80.59 10,050 
7,605 87.66 667 
10,532 94.94 1,000 
161,912 114.26 18,500 
3,197,631 $174,985 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 
Six months ended June 30,Year ended December 31,
2022
20232022
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-6.00
5.33-5.83
5.33-5.83
Expected volatility
63%-67%
60%-62%
60%-62%
Risk-free interest rate
3.48%-4.10%
1.58%-3.04%
1.58%-4.23%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility56 %51 %
51%-77%
Risk-free interest rate4.76 %0.19 %
0.19%-2.52%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2023 and 2022, and the year ended December 31, 2022 was:
Three months ended June 30,Six months ended June 30,Year ended December 31,
2022
2023202220232022
UnauditedUnauditedAudited
Cost of revenues$2,023 $1,029 $4,029 $1,981 $4,690 
Research, development and clinical studies8,537 7,624 20,316 14,425 30,790 
Sales and marketing10,213 6,802 21,857 13,457 28,826 
General and administrative11,967 10,368 25,622 21,005 42,649 
Total share-based compensation expense$32,740 $25,823 $71,824 $50,868 $106,955